#United States #Hollywood #PBM Reform #drug costs #US-Rx Care

Increased Oversight in Pharmacy Benefit Management

In early 2026, significant reforms in pharmacy benefit management (PBM) have shifted from mere policy discussions to a reality where employers must navigate heightened scrutiny regarding drug purchasing. US-Rx Care emphasizes that self-funded employers are now under increasing pressure to align with fiduciary responsibility. While many troubling aspects of PBM operations remain unchanged, the narrative has transitioned to one where employers need to justify their choices in a climate of increasing distrust.

The Changing Landscape for Employers

The enactment of the Consolidated Appropriations Act of 2026 marked a pivotal moment in PBM reform. Regulatory bodies, particularly the Department of Labor, have put forward proposals regarding fee transparency for self-insured plans. Given these changes, plan sponsors are not solely concerned about PBMs facing criticism but are now more focused on proving due diligence in their pharmacy benefits governance.

Renzo Luzzatti, CEO of US-Rx Care, articulates this new reality succinctly: "Employers do not have to wait for every rule to be finalized. They can demand fiduciary alignment now, addressing conflicts directly in their pharmacy benefit purchasing."

This aligns with the shifting expectations surrounding oversight duties, especially as addressable governance matters rise for finance chiefs and procurement teams who oversee pharmacy expenditures.

Scrutiny of Legacy Structures

Despite the buzz surrounding reform headlines, many structural factors that inflate drug costs for employers remain intact. US-Rx Care highlights several persistent issues, including:

• - Vertically integrated pharmacy ownership, which limits competition.
• - Exclusive contracts that bind plans to PBM-controlled services.
• - Economic models tied to rebates, which can obscure actual costs.
• - Prior authorization controls and other terms that favor PBMs financially even as expenses for plans increase.

These elements contribute to a perception of stability amidst ongoing reform discussions, presenting risk for employers who may prematurely presume that reforms created a safer marketplace.

The Importance of Comprehensive Transparency

With recent calls for heightened transparency, it's crucial to understand what disclosures are truly meaningful. US-Rx Care asserts that legacy PBMs often resist revealing their total revenues, including funds derived from manufacturer deals or pharmacy ownership arrangements. Such undisclosed earnings frequently lead to conflicts of interest that adversely affect both plan sponsors and members.

Luzzatti remarks, "Before employers can address economic disparities in benefits, they must understand the full financial picture—such as who receives payments, how they are structured, and whether increasing plan costs merely enhance PBM profitability."

Questions for Renewal and Future Contracts

In the current climate, US-Rx Care urges employers to adopt a critical mindset vis-à-vis their upcoming PBM contracts. They recommend asking key questions that include:

• - Is the PBM aligned with my ERISA fiduciary obligations?
• - Does the PBM profit when our overall plan expenses escalate?
• - Are we compelled to utilize particular pharmacies owned by the PBM due to contract stipulations?

These inquiries ascertain whether employers engage with genuinely protective contractual agreements or are exposed to performative transparency.

Demand for Fiduciary Standards

US-Rx Care envisions a paradigm shift toward fiduciary standards rather than merely increasing transparency in contract language, which can inherently lack accountability. As Luzzatti states, "Transparency can mean anything PBMs want it to; fiduciary duty, however, comes with robust legal backing under ERISA."

For employers seeking prudent renewal strategies this year, the emphasis is on recognizing specific provisions that exacerbate PBM power. For example, clauses stating that the PBM is not a fiduciary or encumber the use of third-party solutions must be critically evaluated.

US-Rx Care advocates for an operational model void of conflicts—no pharmacy ownership, clear administrative fees, and formularies developed with a focus on driving net cost efficiency without compromising care quality. This proactive approach will help employers transcend superficial reforms and truly safeguard their interests in pharmacy benefits management.

Conclusion

As the PBM landscape continues to evolve, employers are urged to take their commitments seriously and act decisively to remove conflicts that compromise their pharmacy benefit management. Reflecting on the past, the lessons are clear—waiting for legislative clarity may not suffice. The call for action is now, and strategic moves can reshape the future of pharmacy benefits for employers across the country.